منابع مشابه
Monoclonal antibodies targeting CD20
We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of mAbs. 1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20 + hema-tological malignancies, 2,3 and also has been studied in a large number of autoimmune ...
متن کاملResponse to: Monoclonal antibodies targeting CD20
the standard rituximab regimen of 375 mg/mm2 based solely on a historical comparison of complete response (CR)/uncon-firmed CR rates from non-randomized Phase 1/2 clinical trials in (relapsed/refractory) follicular non-Hodgkin lymphoma (NHL) patients as it is stated in the letter of Goldenberg and colleagues. In line with this, the cited publications by Morschhauser et al. 5 and Negrea et al. 6...
متن کاملNovel CD20 monoclonal antibodies for lymphoma therapy
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphom...
متن کاملMonoclonal Antibodies
SUMMARY Monoclonal Antibodies are identical antibodies and Can be generated in ultimated amounts by countinuos cultures of single antibody- secreting cells. These cell lines are produced by cell fusion of normal lymphocytes to cells of a myeloma tumor cell line, which confers on the antibody producing hybrid cell, immortality and the ability grow as atumor in animals. monoclonal antibodies c...
متن کاملAnti-CD20 monoclonal antibodies: historical and future perspectives.
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: mAbs
سال: 2013
ISSN: 1942-0862,1942-0870
DOI: 10.4161/mabs.24106